Abstract
The article provides an analysis of the latest antiepileptic drug eslicarbazepine acetate (ESL) for the treatment of focal epilepsy in adults as monotherapy and adjunctive therapy. Pharmacokinetics, pharmacodynamics, drug-drug interactions, indications and dosage regimen are described. The authors present the latest data on the efficacy, tolerability and safety of ESL including an exploratory pooled analysis of data from 14 European clinical practice studies (Euro-Esli) as well as their own observations of 34 patients receiving ESL in monotherapy or combination therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
